Pharmacokinetic analysis and uptake of 18f-fbpa-fr after ultrasound-induced blood-brain barrier disruption for potential enhancement of boron delivery for neutron capture therapy

Journal of Nuclear Medicine

Volumn 55, Issue 4, 2014, Pages 616-621

  Yang, Feng Yi ^a   Chang, Wen Yuan ^a   Li, Jia Je ^a   Wang, Hsin Ell ^a   Chen, Jyh Cheng ^a   Chang, Chi Wei ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Blood brain barrier; Boron neutron capture therapy; Focused ultrasound; Pharmacokinetics

Indexed keywords

4 BORONO 2 FLUORO PHENYLALANINE FRUCTOSE F 18; BORON; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD BRAIN BARRIER; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG ACCUMULATION; DRUG UPTAKE; ECHOGRAPHY; GLIOMA; IMAGE ANALYSIS; MALE; NEUTRON CAPTURE THERAPY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; RAT; TUMOR XENOGRAFT;

18F-FBPA-FR; BLOOD-BRAIN BARRIER; BORON NEUTRON CAPTURE THERAPY; FOCUSED ULTRASOUND; PHARMACOKINETICS;

ANIMALS; APOPTOSIS; BLOOD-BRAIN BARRIER; BORON COMPOUNDS; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; GLIOMA; GLYCOPEPTIDES; IN SITU NICK-END LABELING; MALE; NEOPLASM TRANSPLANTATION; NEUTRON CAPTURE THERAPY; PHENYLALANINE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, INBRED F344; ULTRASONICS;

EID: 84901359863     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.125716     Document Type: Article

References (41)

1. Sweet WH. Early history of development of boron neutron capture therapy of tumors. J Neurooncol. 1997;33:19-26.
2. Asbury AK, Ojemann RG, Nielsen SL, Sweet WH. Neuropathologic study of fourteen cases of malignant brain tumor treated by boron-10 slow neutron capture radiation. J Neuropathol Exp Neurol. 1972;31:278-303.
3. Hatanaka H. Experience of boron-neutron capture therapy for malignant brain tumours-with special reference to the problems of postoperative CT follow-ups. Acta Neurochir Suppl (Wien). 1988;42:187-192.
4. Barth RF, Vicente MG, Harling OK, et al. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat Oncol. 2012;7:146-166.
5. Barth RF. Boron neutron capture therapy at the crossroads: challenges and opportunities. Appl Radiat Isot. 2009;67(suppl):S3-S6.
6. Barth RF, Yang W, Huo T, et al. Comparison of intracerebral delivery of carboplatin and photon irradiation with an optimized regimen for boron neutron capture therapy of the F98 rat glioma. Appl Radiat Isot. 2011;69:1813-1816.
7. Barth RF, Coderre JA, Vicente MG, Blue TE. Boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res. 2005;11:3987-4002.
8. Soloway AH, Tjarks W, Barnum BA, et al. The chemistry of neutron capture therapy. Chem Rev. 1998;98:1515-1562.
9. Black KL, Ningaraj NS. Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor. Cancer Control. 2004;11:165-173.
10. Sköld K, H-Stenstam B, Diaz AZ, Giusti V, Pellettieri L, Hopewell JW. Boron neutron capture therapy for glioblastoma multiforme: advantage of prolonged infusion of BPA-f. Acta Neurol Scand. 2010;122:58-62.
11. Miyatake S, Kawabata S, Yokoyama K, et al. Survival benefit of boron neutron capture therapy for recurrent malignant gliomas. J Neurooncol. 2009;91:199-206.
12. Miyatake S, Tamura Y, Kawabata S, Iida K, Kuroiwa T, Ono K. Boron neutron capture therapy for malignant tumors related to meningiomas. Neurosurgery. 2007;61:82-90.
13. Kawabata S, Hiramatsu R, Kuroiwa T, Ono K, Miyatake S. Boron neutron capture therapy for recurrent high-grade meningiomas. J Neurosurg. 2013;119: 837-844.
14. Sköld K, Gorlia T, Pellettieri L, Giusti V, H-Stenstam B, Hopewell JW. Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential. Br J Radiol. 2010;83:596-603.
15. Kankaanranta L, Seppala T, Koivunoro H, et al. L-Boronophenylalanine- mediated boron neutron capture therapy for malignant glioma progressing after external beam radiation therapy: a phase I study. Int J Radiat Oncol Biol Phys. 2011;80:369-376.
16. Barth RF, Yang W, Bartus RT, et al. Neutron capture therapy of intracerebral melanoma: enhanced survival and cure after blood-brain barrier opening to improve delivery of boronophenylalanine. Int J Radiat Oncol Biol Phys. 2002;52: 858-868.
17. Barth RF, Yang W, Rotaru JH, et al. Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood-brain barrier disruption. Cancer Res. 1997;57:1129-1136.
18. Hsieh CH, Chen YF, Chen FD, et al. Evaluation of pharmacokinetics of 4-borono-2-18F-fluoro-l-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. J Nucl Med. 2005;46:1858-1865.
19. Abbott NJ, Romero IA. Transporting therapeutics across the blood-brain barrier. Mol Med Today. 1996;2:106-113.
20. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery. 1998;42:1083-1099.
21. Yang FY, Lee PY. Efficiency of drug delivery enhanced by acoustic pressure during blood-brain barrier disruption induced by focused ultrasound. Int J Nanomedicine. 2012;7:2573-2582.
22. Yang FY, Wang HE, Lin GL, Lin HH, Wong TT. Evaluation of the increase in permeability of the blood-brain barrier during tumor progression after pulsed focused ultrasound. Int J Nanomedicine. 2012;7:723-730.
23. Yang FY, Lin GL, Horng SC, et al. Pulsed high-intensity focused ultrasound enhances the relative permeability of the blood-tumor barrier in a gliomabearing rat model. IEEE Trans Ultrason Ferroelectr Freq Control. 2011;58: 964-970.
24. Yang FY, Liu SH, Ho FM, Chang CH. Effect of ultrasound contrast agent dose on the duration of focused-ultrasound-induced blood-brain barrier disruption. J Acoust Soc Am. 2009;126:3344-3349.
25. McDannold N, Vykhodtseva N, Hynynen K. Effects of acoustic parameters and ultrasound contrast agent dose on focused-ultrasound induced blood-brain barrier disruption. Ultrasound Med Biol. 2008;34:930-937.
26. Yang FY, Horng SC, Lin YS, Kao YH. Association between contrast-enhanced MR images and blood-brain barrier disruption following transcranial focused ultrasound. J Magn Reson Imaging. 2010;32:593-599.
27. Yang FY, Teng MC, Lu M, et al. Treating glioblastoma multiforme with selective high-dose liposomal doxorubicin chemotherapy induced by repeated focused ultrasound. Int J Nanomedicine. 2012;7:965-974.
28. Yang FY, Wong TT, Teng MC, et al. Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme. J Control Release. 2012;160: 652-658.
29. Yang FY, Chen YW, Chou FI, Yen SH, Lin YL, Wong TT. Boron neutron capture therapy for glioblastoma multiforme: enhanced drug delivery and antitumor effect following blood-brain barrier disruption induced by focused ultrasound. Future Oncol. 2012;8:1361-1369.
30. Yang FY, Wang HE, Lin GL, et al. Micro-SPECT/CT-based pharmacokinetic analysis of 99mTc-diethylenetriaminepentaacetic acid in rats with blood-brain barrier disruption induced by focused ultrasound. J Nucl Med. 2011;52:478-484.
31. Yang FY, Wang HE, Liu RS, et al. Pharmacokinetic analysis of 111In-labeled liposomal doxorubicin in murine glioblastoma after blood-brain barrier disruption by focused ultrasound. PLoS One. 2012;7:e45468.
32. Wang HE, Liao AH, Deng WP, et al. Evaluation of 4-borono-2-18F-fluoro-L- phenylalanine-fructose as a probe for boron neutron capture therapy in a gliomabearing rat model. J Nucl Med. 2004;45:302-308.
33. Yang FY, Lin YS, Kang KH, Chao TK. Reversible blood-brain barrier disruption by repeated transcranial focused ultrasound allows enhanced extravasation. J Control Release. 2011;150:111-116.
34. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131-137.
35. Imahori Y, Ueda S, Ohmori Y, et al. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part II. Clin Cancer Res. 1998;4:1833-1841.
36. Yoshino K, Suzuki A, Mori Y, et al. Improvement of solubility of p-boronophenylalanine by complex formation with monosaccharides. Strahlenther Onkol. 1989;165:127-129.
37. Ishiwata K, Shiono M, Kubota K, et al. A unique in vivo assessment of 4-[10B] borono-L-phenylalanine in tumour tissues for boron neutron capture therapy of malignant melanomas using positron emission tomography and 4-borono-2-[18F] fluoro-L-phenylalanine. Melanoma Res. 1992;2:171-179.
38. Yang W, Barth RF, Rotaru JH, et al. Enhanced survival of glioma bearing rats following boron neutron capture therapy with blood-brain barrier disruption and intracarotid injection of boronophenylalanine. J Neurooncol. 1997;33: 59-70.
39. Yang W, Barth RF, Rotaru JH, et al. Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of sodium borocaptate with or without blood-brain barrier disruption. Int J Radiat Oncol Biol Phys. 1997;37:663-672.
40. Smith DR, Chandra S, Barth RF, Yang W, Joel DD, Coderre JA. Quantitative imaging and microlocalization of boron-10 in brain tumors and infiltrating tumor cells by SIMS ion microscopy: relevance to neutron capture therapy. Cancer Res. 2001;61:8179-8187.
41. Frenkel V, Etherington A, Greene M, et al. Delivery of liposomal doxorubicin (Doxil) in a breast cancer tumor model: investigation of potential enhancement by pulsed-high intensity focused ultrasound exposure. Acad Radiol. 2006;13: 469-479.